Platform Driven Partnerships Piton's proprietary AI-enabled platform identifies gut-lumen drug candidates and validates them in-house, enabling faster discovery of first-in-class small molecules. This capability positions Piton as a potential partner for pharma seeking to de-risk gut-targeted programs through collaboration or licensing of discovery assets and platform access.

UC and ASD Opportunity Lead programs target Ulcerative Colitis with a clinically notable sub-type and an Autism program with in vivo validation, while Parkinson's remains a broader focus. Business development opportunities include licensing or co-development of UC and ASD assets and exploring cross-indication collaborations with PD.

Cross Indication Growth The therapeutic strategy shows potential beyond GI and neurodevelopment, with indications in metabolic areas such as diabetes and weight management under consideration. This supports a multi-indication partnering approach to expand the platform's reach.

Clinical Timelines Near-term clinical milestones could unlock partnership opportunities with milestone-based economics. Engaging Piton early in the development process may yield favorable terms for exclusive licenses or joint development deals tied to clinical progress.

IP and Advisory A strong IP portfolio and active advisory network underpin credible execution and risk-adjusted partnerships. Leverage these assets in negotiations to secure exclusive rights and governance favorable to co-development within Piton's biotech ecosystem.